Biotech Values

[DewDiligence]

ENTA’s cash balance at 9/30/12 was $112.2M; cash usage using during FY4Q13 was only $2.6M:

http://finance.yahoo.com/news/enanta-pharmaceuticals-reports-financial-results-123000980.html

Given the $195M in pre-commercial milestones expected from ABBV for regulatory filing ($40M in calendar 2Q14) and regulatory approval ($150M expected in early calendar 2015) of ABBV’s 3-DAA HCV regimen (#msg-91918990), it’s clear that ENTA does not have a liquidity probem.